Xanthine phosphodiesterase V inhibitor polymorphs

Details Xanthine phosphodiesterase V inhibitor polymorphs Xanthine phosphodiesterase V inhibitor polymorphs

2007-03-20

2007-03-20

Berch, Mark L. (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S263320, C514S263360, C544S272000

Reexamination Certificate

active

10449650

ABSTRACT:
Crystalline polymorphs of 1-ethyl-3,7-dihydro-8-[(1R,2R) -(hydroxycyclopentyl)amino]-3-(2-hydroxyethyl)-7-[(3-bromo-4-methoxyphenyl)methyl]-1H-Purine-2,6-dione in Form 1 and Form 2, which exhibit x-ray powder diffraction profiles substantially the same as those shown in FIGS.5and6, respectively, and which exhibit differential scanning calorimtery profiles substantially the same as those shown in FIGS.2and4, respectively, and are represented by the formula:Pharmaceutical compositions comprising the polymorph Form 1 or 2 of Compound 13 and at least one excipient or carrier, and methods of using the polymorph Form 1 or 2 of Compound 13 to treat a variety of physiological disorders, such as erectile dysfunction.

REFERENCES:
patent: 6469012 (2002-10-01), Ellis et al.
patent: 2006/0205943 (2006-09-01), Dahanukar et al.
patent: WO 099/20625 (1999-04-01), None
patent: WO 02/24698 (2002-03-01), None
International Search Report, May 30, 2003, PCT/US03/16890.

Affiliated with

Also associated with

Rating

Xanthine phosphodiesterase V inhibitor polymorphs does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Xanthine phosphodiesterase V inhibitor polymorphs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Xanthine phosphodiesterase V inhibitor polymorphs will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3796221